Your browser doesn't support javascript.
loading
UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology.
Price, Meghan J; Nguyen, Annee D; Byemerwa, Jovita K; Flowers, Jasmine; Baëta, César D; Goodwin, C Rory.
Afiliação
  • Price MJ; Department of Internal Medicine, John Hopkins Hospital, Baltimore, MD 21287, USA.
  • Nguyen AD; Department of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA.
  • Byemerwa JK; Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27708, USA.
  • Flowers J; Department of Neurosurgery, Associated with Duke University Medical Center, Durham, NC 27710, USA.
  • Baëta CD; Department of Epidemiology and Clinical Research, Stanford University, Stanford, CA 94305, USA.
  • Goodwin CR; Department of Neurosurgery, Duke Center for Brain and Spine Metastasis and Duke Cancer Institute, Durham, NC 27710, USA.
Oncotarget ; 14: 843-857, 2023 09 28.
Article em En | MEDLINE | ID: mdl-37769033
ABSTRACT
UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key reaction in hormone and xenobiotic metabolism and in the production of extracellular matrix precursors. In this review, we classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describe its involvement in key canonical cancer signaling pathways, and identify methods to inhibit UGDH, its substrates, and its downstream products. As such, we position UGDH as an enzyme to be exploited as a potential prognostication marker in oncology and a therapeutic target in cancer biology.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Uridina Difosfato Glucose Desidrogenase / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Uridina Difosfato Glucose Desidrogenase / Neoplasias Idioma: En Ano de publicação: 2023 Tipo de documento: Article